CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Market Closed - Nyse Other stock markets 21:00:02 06/02/2026 GMT			5-day change	1st Jan Change
189.21 ^USD	+3.00%		-10.11%	-5.15%

01-22	TD Cowen Adjusts Price Target on Charles River Laboratories International to $251 From $197, Maintains Buy Rating	MT
01-21	Charles River Laboratories International, Inc. Enters Manufacturing Collaboration with Gazi University	CI

Transcript : Charles River Laboratories International, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10

Published on 01/13/2026 at 07:35 pm GMT - Modified on 01/13/2026 at 09:06 pm GMT

S&P Capital IQ

Presenter Speech
Casey Woodring (Analysts)

Hi, everybody. Welcome to the JPMorgan Healthcare Conference. I'm Casey Woodring from the Life Science Tools and Diagnostics team. Pleased to be joined by

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Charles River Laboratories International, Inc.

01-22	TD Cowen Adjusts Price Target on Charles River Laboratories International to $251 From $197, Maintains Buy Rating	MT
01-21	Charles River Laboratories International, Inc. Enters Manufacturing Collaboration with Gazi University	CI
01-21	Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	MT
01-21	When America Starts to Feel Like a Risky Asset
01-21	Charles River Enters Into Manufacturing Collaboration With Gazi University	MT
01-20	Jefferies Adjusts Price Target on Charles River Laboratories International to $255 From $205, Maintains Buy Rating	MT
01-20	Greenland, Tariffs, and the Quiet Revolt of the Bond Market
01-20	Analyst recommendations: Intel, Philip Morris, Duolingo, Netflix, SanDisk…
01-16	Citigroup Adjusts Price Target on Charles River Laboratories International to $265 From $200, Maintains Buy Rating	MT
01-13	Charles River Laboratories International, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
01-13	Charles River Laboratories International Seeks Acquisitions	CI
01-13	Baird Adjusts PT on Charles River Laboratories International to $231 From $224, Keeps Outperform Rating	MT
01-13	Evercore ISI Adjusts PT on Charles River Laboratories International to $260 From $250, Maintains Outperform Rating	MT
01-12	Charles River Laboratories Reports Two Planned Acquisitions; Names Namandje Bumpus as Chief Scientific and Innovation Officer	MT
01-12	Charles River to buy Cambodia-based monkey supplier for $510 million	RE
01-12	Charles River Laboratories provides business updates	RE
01-12	Charles River Laboratories Names Dr. Namandjé N. Bumpus as Senior Vice President, Chief Scientific and Innovation Officer	CI
01-11	Charles River Laboratories International, Inc. exercised its option to acquire remaining 79% stake in PathoQuest SAS for ?51.6 million.	CI
01-11	Charles River Laboratories International, Inc. entered into agreement to acquire Assets of K.F. Ltd. from K.F. Ltd. for $510 million.	CI
01-11	Charles River Laboratories International, Inc. entered into agreement to acquire Assets of K.F. Ltd. from K.F. Ltd. for $510 million.	CI
01-09	Mizuho Adjusts Price Target on Charles River Laboratories International to $215 From $200, Maintains Neutral Rating	MT
01-08	Charles River Laboratories International, Inc. Announces Chief Executive Officer Changes	CI
01-08	Charles River Laboratories International, Inc. Announces Changes in Board	CI
01-08	Peace Was Cheaper
01-08	Charles River Laboratories International, Chair, President, CEO James Foster to Retire	MT